Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in respo…

Lymphoma, Non-Hodgkin Lymphoma, B-Cell

~Estimated

~$10 – $8,750

Luminary TherapeuticsNCT05312801

Phase 1

A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult pati…

Hematologic MalignancyAMLALL+8 more

~Estimated

~$10 – $7,500

Therapeutic Advances in Childhood Leukemia ConsortiumNCT05476770

← PreviousPage 2 of 2Next →